2-hydroxy-N-pentylbenzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-hydroxy-N-pentylbenzamide
• 化学式: C₁₂H₁₇NO₂
• mdl: MFCD11130895
• 分子量: 207.272
• InChiKey: MCLLHXMOCPSMBZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  草酰氯 、 2-hydroxy-N-pentylbenzamide 以 甲苯 为溶剂， 反应 4.0h， 生成 3-Pentyl-benzo[e][1,3]oxazine-2,4-dione
  参考文献：
  名称：

  Zaleska; Lis, Pharmazie, 1995, vol. 50, # 2, p. 150 - 151

  摘要：

  DOI：
• 作为产物：
  描述：

  2-iodo-N-pentylbenzamide 在 1,10-菲罗啉 、 copper(I) bromide 、 lithium hydroxide 作用下， 以 二甲基亚砜 为溶剂， 反应 12.0h， 以82%的产率得到2-hydroxy-N-pentylbenzamide
  参考文献：
  名称：

  铜催化串联芳基-卤素羟基化和基于CH 2 Cl 2的N，O-缩醛化反应合成2,3-二氢苯并恶嗪酮†

  摘要：

  2,3-二氢-4 H-苯并[ e ] [1,3]恶嗪-4-酮的简明合成是通过铜催化邻卤代苯甲酰胺，LiOH和二氯甲烷的串联反应完成的。CH 2 Cl 2上的芳基-卤素键羟基化以及随后的N，O-缩醛化在催化条件下得以实现，该条件允许生成C（sp 2）-O，C（sp 3）-O和C（sp 3）- N键可提供目标产品。

  DOI：

  10.1039/c7ob00625j

文献信息

• [EN] CARBOXYL SUBSTITUTED INDOLES FOR USE AS PPAR ALPHA MODULATORS<br/>[FR] INDOLES À SUBSTITUTION CARBOXYLE DESTINÉS À ÊTRE UTILISÉS EN TANT QUE MODULATEURS DU PPAR-ALPHA
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009147121A1

  公开（公告）日：2009-12-10

  There is provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts or solvates thereof wherein one of R1 and R2 is H and the other is COOH. The compounds are useful as PPAR modulators.

  根据本发明提供了式(I)的新化合物或其药用可接受的盐或溶剂，其中R1和R2中的一个是H，另一个是COOH。这些化合物可用作PPAR调节剂。
• [EN] NOVEL COMPOUNDS<br/>[FR] COMPOSÉS INÉDITS
  申请人：GLAXO GROUP LTD

  公开号：WO2011038572A1

  公开（公告）日：2011-04-07

  The present invention discloses novel compounds inhibiting LRRK2 kinase activity, the preparation processes thereof, the compositions containing them, as well as the use in treating diseases characterized by LRRK2 kinase activity, particularly Parkinson's disease and Alzheimer's disease.

  本发明公开了抑制LRRK2激酶活性的新化合物，其制备过程，含有它们的组合物，以及在治疗以LRRK2激酶活性为特征的疾病中的应用，特别是帕金森病和阿尔茨海默病。
• Fast synthesis of amides from ethyl salicylate under microwave radiation in a solvent-free system
  作者：Rafaely N. Lima、Valdenizia R. Silva、Luciano de S. Santos、Daniel P. Bezerra、Milena B. P. Soares、André L. M. Porto

  DOI：10.1039/c7ra11434f

  日期：——

  The reaction employing CAL-B also permitted a moderate conversion for the production of amides S-Ae-Aj (3–42%). However, in our efforts to reduce the amide synthesis time (24 h), the reactions were performed in the presence of microwave-MW radiation using a free-solvent system [60 °C, PBA (15 mol%) or WC], which reduced the time of the reaction by 32-fold (45 min) and afforded nine amides (S-Aa-Ah and

  在这项研究中，酰胺键的形成是有机化学中最重要的反应之一，使用水杨酸乙酯和十种不同的伯胺对其进行了评估。在最优化的实验条件下，即60°C，己烷，苯基硼酸-PBA（15 mol％），硼酸-BA（15 mol％）或不使用催化剂-WC的条件下，使用加热板放置24 h，可获得酰胺具有出色的孤立产量（WC，占S-Aa-Ad的77-94％； PBA，占S-Ae-Aj的11-94％；以及BA，占S-Ae-Aj的28-90％）。使用CAL-B的反应还允许适度转化生成酰胺S-Ae-Aj（3–42％）。但是，在我们减少酰胺合成时间（24小时）的努力中，反应是在微波-微波辐射存在下使用自由溶剂系统[60°C，PBA（15摩尔％）或WC]进行的，将反应时间减少了32倍（45分钟），得到了9种酰胺（S-Aa-Ah和S-Aj），分离产率为80-99％，S-Ai的产率为23％。细胞毒性分析表明，酰胺S-银是能够与IC抑制
• O-substituted hydroxyaryl derivatives
  申请人：Muto Susumu

  公开号：US20060094718A1

  公开（公告）日：2006-05-04

  A medicament having inhibitory activity against NF-κB activation which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in a main chain is 2 to 5 (said connecting group may be substituted), “A” represents an acyl group which may be substituted, (provided that unsubstituted acetyl group and unsubstituted acryloyl group are excluded,) or a C 1 to C 6 alkyl group which may be substituted, or A may bind to connecting group X to form a cyclic structure which may be substituted, “E” represents an aryl group which may be substituted or a heteroaryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.

  一种药物具有抑制NF-κB激活活性，其包括以下通式(I)所表示的化合物或其药学上可接受的盐、水合物或溶剂化物作为活性成分，其中X表示主链中原子数为2至5的连接基（该连接基可以被取代），A表示可以被取代的酰基（不包括未取代的乙酰基和未取代的丙烯酰基）或者可以被取代的C1到C6烷基，或者A可以与连接基X结合形成可以被取代的环状结构，E表示可以被取代的芳基或者可以被取代的杂环基，环Z表示可以具有一个或多个取代基的芳基（除了由式—O-A所表示的基团外，A具有与上述定义相同的含义，由式—X-E所表示的基团，X和E具有与上述定义相同的含义）或者可以具有一个或多个取代基的杂环基（除了由式—O-A所表示的基团外，A具有与上述定义相同的含义，由式—X-E所表示的基团，X和E具有与上述定义相同的含义）。
• Inhibitors against the activation of ap-1 and nfat
  申请人：Muto Susumu

  公开号：US20060100257A1

  公开（公告）日：2006-05-11

  A medicament inhibiting the activation of AP-1 which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.

  一种药物，抑制AP-1的激活，其活性成分为以下通式（I）所表示的化合物或其药学上可接受的盐、水合物或溶剂化物中所选的一种，其中X代表连接基，其主链中的原子数为2至5（该连接基可以被取代），A代表氢原子或乙酰基，E代表芳基或取代的杂芳基，环Z代表芳烃，除了由式—O-A所表示的基团外，可能还有一个或多个取代基，其中A具有上述定义的相同含义，由式—X-E所表示的基团中，X和E的每一个具有上述定义的相同含义，或者是一个杂芳烃，可能还有一个或多个取代基，其中A具有上述定义的相同含义，由式—X-E所表示的基团中，X和E的每一个具有上述定义的相同含义。